SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype
暂无分享,去创建一个
C. O'keefe | M. Sekeres | H. Makishima | F. Traina | H. Rogers | V. Visconte | R. Tiu | A. Lichtin | B. Hamilton | E. Hasrouni | A. Tabarroki | F. Hsieh | L. Horwitz | Yang Liu | H. J. Rogers | Edy Hasrouni
[1] J. Valcárcel,et al. The spliceosome as a target of novel antitumour drugs , 2012, Nature Reviews Drug Discovery.
[2] A. Jankowska,et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. , 2012, Blood.
[3] S. T. Olalla Saad,et al. Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis , 2012, PloS one.
[4] J. Maciejewski,et al. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders , 2012, Leukemia.
[5] Michael Heuser,et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. , 2012, Blood.
[6] A. Jankowska,et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. , 2012, Blood.
[7] A. Jankowska,et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts , 2012, Leukemia.
[8] Li Ding,et al. RECURRENT MUTATIONS IN THE U2AF1 SPLICING FACTOR IN MYELODYSPLASTIC SYNDROMES , 2011, Nature Genetics.
[9] M. Stratton,et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.
[10] S. Sugano,et al. Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.
[11] D. Douek,et al. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. , 2011, Blood.
[12] C. O'keefe,et al. Deletions of Xp22.2 including PIG-A locus lead to paroxysmal nocturnal hemoglobinuria , 2011, Leukemia.
[13] N. Young,et al. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR β-CDR3 sequencing , 2004, The Lancet.
[14] M. Arock,et al. c‐Kit and c‐kit mutations in mastocytosis and other hematological diseases , 2000, Journal of leukocyte biology.